{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T17:52:01Z","timestamp":1792173121983,"version":"4.4.0"},"reference-count":49,"publisher":"Informa UK Limited","issue":"9","license":[{"start":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T00:00:00Z","timestamp":1775433600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T00:00:00Z","timestamp":1775433600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncology"],"published-print":{"date-parts":[[2026,4,9]]},"DOI":"10.1080\/14796694.2026.2651961","type":"journal-article","created":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T12:36:31Z","timestamp":1775478991000},"page":"1073-1082","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":2,"title":["SUNRAY-01 trial protocol: an innovative study design of olomorasib and pembrolizumab with or without chemotherapy in\n                    <i>KRAS<\/i>\n                    G12C NSCLC"],"prefix":"10.1080","volume":"22","author":[{"given":"Solange","family":"Peters","sequence":"first","affiliation":[{"name":"Lausanne University and CHUV","place":["Lausanne, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Hochmair","sequence":"additional","affiliation":[{"name":"Karl Landsteiner Institute for Lung Research and Pulmonary Oncology, Klinik Floridsdorf","place":["Vienna, Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn C.","family":"Arbour","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center","place":["New York, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis Paz-Ares","family":"Rodriguez","sequence":"additional","affiliation":[{"name":"Universidad Complutense de Madrid","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Reck","sequence":"additional","affiliation":[{"name":"LungenClinic Grosshansdorf, Airway Research Center North (ARCN)","place":["Grosshansdorf, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ticiana","family":"Leal","sequence":"additional","affiliation":[{"name":"Winship Cancer Institute, Emory University","place":["Atlanta, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin","family":"R. Lindsay","sequence":"additional","affiliation":[{"name":"The Christie NHS Foundation Trust","place":["Manchester, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Shun","sequence":"additional","affiliation":[{"name":"Shangai Jiaotong University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William Nassib","family":"William","sequence":"additional","affiliation":[{"name":"Grupo Oncocl\u00ednicas","place":["S\u00e3o Paulo, Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander I.","family":"Spira","sequence":"additional","affiliation":[{"name":"Virginia Cancer Specialists","place":["Fairfax, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua K.","family":"Sabari","sequence":"additional","affiliation":[{"name":"NYU Langone Health","place":["New York, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f8rn","family":"Henning Gr\u00f8nberg","sequence":"additional","affiliation":[{"name":"NTNU, Norwegian University of Science and Technology","place":["Trondheim, Norway"]},{"name":"St. Olavs Hospital, Trondheim University Hospital","place":["Trondheim, Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Nishio","sequence":"additional","affiliation":[{"name":"Cancer Institute Hospital of Japanese Foundation for Cancer Research","place":["Tokyo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy F.","family":"Burns","sequence":"additional","affiliation":[{"name":"The Ohio State University Comprehensive Cancer Center","place":["Colombus, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Girard","sequence":"additional","affiliation":[{"name":"Institut Curie","place":["Paris, France"]},{"name":"Paris Saclay University","place":["Versailles, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederico","family":"Capuzzo","sequence":"additional","affiliation":[{"name":"IRCCS Regina Elena National Cancer Institute","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyson","family":"Merced","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company","place":["Indianapolis, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Fasnacht","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company","place":["Indianapolis, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Visseren-Grul","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company","place":["Indianapolis, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelo V.","family":"Negrao","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center","place":["Houston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,4,6]]},"reference":[{"key":"e_1_3_8_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606774"},{"key":"e_1_3_8_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801005"},{"key":"e_1_3_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.12.013"},{"key":"e_1_3_8_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-01062"},{"key":"e_1_3_8_7_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2025.0043"},{"key":"e_1_3_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2019.01.020"},{"key":"e_1_3_8_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01626"},{"key":"e_1_3_8_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2030638"},{"key":"e_1_3_8_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/PO.21.00245"},{"key":"e_1_3_8_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0000000000000305"},{"key":"e_1_3_8_13_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.4427"},{"key":"e_1_3_8_14_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-21-1331"},{"key":"e_1_3_8_15_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-0383"},{"key":"e_1_3_8_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00046"},{"key":"e_1_3_8_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2025.09.434"},{"key":"e_1_3_8_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1917239"},{"key":"e_1_3_8_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204619"},{"key":"e_1_3_8_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2023.100743"},{"key":"e_1_3_8_21_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-3074"},{"key":"e_1_3_8_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-023-01839-y"},{"key":"e_1_3_8_23_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-2554"},{"key":"e_1_3_8_24_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002891"},{"key":"e_1_3_8_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.01.011"},{"key":"e_1_3_8_26_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.0546"},{"issue":"9","key":"e_1_3_8_27_1","first-page":"S10","article-title":"OA03.06 CodeBreaK 100\/101: first report of safety\/efficacy of sotorasib in combination with pembrolizumab or atezolizumab in advanced kras p.G12C NSCLC [Abstract]","volume":"17","author":"Li BT","year":"2022","unstructured":"Li BT, Falchook GS, Durm GS, et al. OA03.06 CodeBreaK 100\/101: first report of safety\/efficacy of sotorasib in combination with pembrolizumab or atezolizumab in advanced kras p.G12C NSCLC [Abstract]. Molec Target Treat. 2022;17(9):S10\u2013S11.","journal-title":"Molec Target Treat"},{"key":"e_1_3_8_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.10.066"},{"key":"e_1_3_8_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1694-1"},{"key":"e_1_3_8_30_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2021-1259"},{"key":"e_1_3_8_31_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2023-CT028"},{"key":"e_1_3_8_32_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2025-CT042"},{"key":"e_1_3_8_33_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.8519"},{"key":"e_1_3_8_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2025.09.109"},{"key":"e_1_3_8_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2025.11.018"},{"key":"e_1_3_8_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2025.09.055"},{"key":"e_1_3_8_37_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.e13561"},{"key":"e_1_3_8_38_1","doi-asserted-by":"publisher","DOI":"10.1080\/07357907.2025.2464684"},{"key":"e_1_3_8_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"e_1_3_8_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-017-2398-8"},{"key":"e_1_3_8_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1556-0864(25)00304-1"},{"key":"e_1_3_8_42_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djaf236"},{"key":"e_1_3_8_43_1","unstructured":"U.S. Department of Health and Human Services Food and Drug Administration (FDA) Oncology Center of Excellence Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER). Cancer clinical trial eligibility criteria: brain metastases guidance for industry. 2020 [cited 2025 Dec 4]. Available from: https:\/\/collections.nlm.nih.gov\/catalog\/nlm:nlmuid-9918227259106676-pdf"},{"key":"e_1_3_8_44_1","unstructured":"Food and Drug Administration. Clinical trial endpoints for the approval of cancer drugs and biologics- guidance for industry 2018. [cited 2025 Dec 4]. Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/clinical-trial-endpoints-approval-cancer-drugs-and-biologics"},{"key":"e_1_3_8_45_1","unstructured":"European Medicines Agency. Guideline on the clinical evaluation of anticancer medicinal products 2023. [cited 2025 Dec 4]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-clinical-evaluation-anticancer-medicinal-products-revision-6_en.pdf"},{"key":"e_1_3_8_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70158-X"},{"key":"e_1_3_8_47_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.672916"},{"key":"e_1_3_8_48_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1816714"},{"key":"e_1_3_8_49_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2306434"},{"key":"e_1_3_8_50_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2306441"},{"key":"e_1_3_8_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2025.09.1025"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14796694.2026.2651961","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/14796694.2026.2651961","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14796694.2026.2651961","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T08:39:51Z","timestamp":1785573591000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14796694.2026.2651961"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,6]]},"references-count":49,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,4,9]]}},"alternative-id":["10.1080\/14796694.2026.2651961"],"URL":"https:\/\/doi.org\/10.1080\/14796694.2026.2651961","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,6]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-12-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}